What is the risk of mortality associated with bleeding in patients with NSTE-ACS?
The ACUITY study suggests that the risk of mortality associated with bleeding is at least as great as that associated with procedure-related or spontaneous MI. Major bleeding is a coprimary endpoint in many trials and is a consideration when assessing the net clinical benefit of a new drug. The incidence of major bleeding in patients with ACS varies widely (0.4% to owing to differing definitions of major bleeding, patient populations, anticoagulation regimens, and PCI or CABG.